Abstract
Cisplatin is the most active single agent in the treatment of epithelial ovarian cancer.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wiltshaw E., Carr B. Cancer Research 48: 178–182, 1984.
Ozols R.F., Corden B.J. Ann. Intern. Med. 100: 19–24, 1984.
Bruckner H.W., Wallach R. Gynecol. Oncol. 12: 64–67, 1924.
Ozols R.F., Young R.C. J. Clin. Oncology 3, N°9: 1246–1250, 1985.
Wiltshaw E., Barker G. J.Clin.Oncology 4, N°5: 722–729, 1986.
Levin L., Hryniuk W.H. J.Clin.Oncology 5, N°5: 756–767, 1987.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Mangioni, C. et al. (1988). Different Platinum Schedules in the Treatment of Epithelial Ovarian Cancer. In: Nicolini, M. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Developments in Oncology, vol 54. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1717-3_45
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1717-3_45
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8967-8
Online ISBN: 978-1-4613-1717-3
eBook Packages: Springer Book Archive